Last reviewed · How we verify
NCT05799118: INHERENT
Study of the Role of Genetic Modifiers in Hemoglobinopathies
trial testing GWAS in Sickle Cell Disease in 30,000 participants. Currently enrolling.
30 September 2027
Quick facts
| Lead sponsor | Cyprus Institute of Neurology and Genetics |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30,000 |
| Start date | 1 October 2022 |
| Primary completion | 30 September 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 26 locations across Denmark, Angola, Italy, Pakistan, Greece, Cyprus, Malaysia, Belgium |
Drugs / interventions tested
- GWAS
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
- Thalassemia, Beta — all drugs for Thalassemia, Beta →
- Thalassemia Alpha — all drugs for Thalassemia Alpha →
- Hemoglobinopathies — all drugs for Hemoglobinopathies →
Sponsor
Cyprus Institute of Neurology and Genetics
Who can join
2 and older, any sex, with Sickle Cell Disease or Thalassemia, Beta. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ethical and regulatory requirements for conducting researcher-driven large-scale multinational genetic haematological studies: the INHERENT experience.
Didio A, Giannuzzi V, Archer N, Gani E, et al · · 2025 · cited 2× · PMID 40765057 · DOI 10.1186/s12961-025-01375-z
Verify or expand the search:
- PubMed search for NCT05799118
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GWAS
Trials testing the same drug.
- NCT06501560 — Profiles Analysis of Genome Wide Association Study (GWAS) in Acne Vulgaris in Indonesia. · NA · recruiting
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05799118 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cyprus Institute of Neurology and Genetics
- Last refreshed: 20 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05799118.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing